SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.44 |
| Enterprise Value ($M) | -7.22 |
| Book Value ($M) | 7.11 |
| Book Value / Share | 1.08 |
| Price / Book | 0.34 |
| NCAV ($M) | -7.57 |
| NCAV / Share | -1.15 |
| Price / NCAV | -0.32 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.86 |
| Return on Assets (ROA) | -0.35 |
| Return on Equity (ROE) | -2.30 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.56 |
| Current Ratio | 1.56 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 12.02 |
| Assets | 26.70 |
| Liabilities | 19.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Bb Biotech Ag | 9.90 | -12.22 | |
| 13G/A | Biotechnology Value Fund L P | 9.99 | 25.18 | |
| 13G/A | Adage Capital Management, L.P. | 0.00 | ||
| 13D/A | Longitude Capital Partners III, LLC | 4.60 | 0.00 | |
| 13D/A | Sante Health Ventures I Lp | 10.10 | -90.61 | |
| 13G/A | Lytton Laurence W | 4.30 | ||
| 13G | Silverarc Capital Management, Llc | 6.60 | ||
| 13G/A | K2 HealthVentures Equity Trust LLC | 9.98 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 215,340 | 1,541,294 | 13.97 | |
| 149,752 | 944,137 | 15.86 | |
| 991,628 | 2,775,421 | 35.73 | |
| 1,199,918 | 3,710,088 | 32.34 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MLTX – MoonLake Immunotherapeutics | MNPR – Monopar Therapeutics Inc. |
| MRKR – Marker Therapeutics, Inc. | MTEX – Mannatech, Incorporated |
| MYNZ – Mainz Biomed N.V. |
Financial data and stock pages provided by
Fintel.io